The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses
- PMID: 36144664
- PMCID: PMC9503362
- DOI: 10.3390/molecules27185928
The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses
Abstract
Viral infection almost invariably causes metabolic changes in the infected cell and several types of host cells that respond to the infection. Among metabolic changes, the most prominent is the upregulated glycolysis process as the main pathway of glucose utilization. Glycolysis activation is a common mechanism of cell adaptation to several viral infections, including noroviruses, rhinoviruses, influenza virus, Zika virus, cytomegalovirus, coronaviruses and others. Such metabolic changes provide potential targets for therapeutic approaches that could reduce the impact of infection. Glycolysis inhibitors, especially 2-deoxy-D-glucose (2-DG), have been intensively studied as antiviral agents. However, 2-DG's poor pharmacokinetic properties limit its wide clinical application. Herein, we discuss the potential of 2-DG and its novel analogs as potent promising antiviral drugs with special emphasis on targeted intracellular processes.
Keywords: 2-deoxy-D-glucose; SARS-CoV-2; glycolysis; glycosylation; metabolic shift; novel analogs; viral infections.
Conflict of interest statement
Moleculin Inc. partially finances research concerning molecular mechanisms of 2-DG analogs, including WP1122 action. W.P. is an inventor of patents covering new derivatives of 2-DG. He is the chair of SAB and a shareholder of Moleculin Biotech. Inc., CNS Pharmaceuticals, and WPD Pharmaceuticals. His research is in part supported by a sponsor research grant from Moleculin Biotech. Inc. and CNS Pharmaceuticals. M.E. is a shareholder of Moleculin Biotech. Inc., and his research is in part supported by a sponsor research grant from Moleculin Biotech. Inc. I.F. and R.Z. are listed as inventors on patents covering new analogs of 2-DG and are consultants of Moleculin Biotech., Inc., and are shareholders of Moleculin Biotech, Inc. and CNS Pharmaceuticals. B.P. is the CSO at WPD Pharmaceuticals. The other authors declare no conflicts of interest.
Figures



Similar articles
-
Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.Life Sci. 2022 Apr 15;295:120411. doi: 10.1016/j.lfs.2022.120411. Epub 2022 Feb 16. Life Sci. 2022. PMID: 35181310 Free PMC article.
-
Glucose and mannose analogs inhibit KSHV replication by blocking N-glycosylation and inducing the unfolded protein response.J Med Virol. 2023 Jan;95(1):e28314. doi: 10.1002/jmv.28314. Epub 2022 Nov 25. J Med Virol. 2023. PMID: 36380418 Free PMC article.
-
Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2.J Virus Erad. 2022 Dec;8(4):100305. doi: 10.1016/j.jve.2022.100305. Epub 2022 Dec 9. J Virus Erad. 2022. PMID: 36514716 Free PMC article.
-
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents.Int J Mol Sci. 2019 Dec 29;21(1):234. doi: 10.3390/ijms21010234. Int J Mol Sci. 2019. PMID: 31905745 Free PMC article. Review.
-
2-Deoxy-d-glucose exploits increased glucose metabolism in cancer and viral-infected cells: Relevance to its use in India against SARS-CoV-2.IUBMB Life. 2021 Oct;73(10):1198-1204. doi: 10.1002/iub.2546. Epub 2021 Sep 2. IUBMB Life. 2021. PMID: 34418270 Free PMC article. Review.
Cited by
-
2-Deoxy-D-Glucose: A Novel Pharmacological Agent for Killing Hypoxic Tumor Cells, Oxygen Dependence-Lowering in Covid-19, and Other Pharmacological Activities.Adv Pharmacol Pharm Sci. 2023 Mar 2;2023:9993386. doi: 10.1155/2023/9993386. eCollection 2023. Adv Pharmacol Pharm Sci. 2023. PMID: 36911357 Free PMC article. Review.
-
Gastrodin inhibits hexokinase-2 mediated glycolysis to rescue rotenone-damaged PC12 cells.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 4. doi: 10.1007/s00210-025-04348-9. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40464941
-
Suppression of Interferon Response and Antiviral Strategies of Bunyaviruses.Trop Med Infect Dis. 2024 Sep 7;9(9):205. doi: 10.3390/tropicalmed9090205. Trop Med Infect Dis. 2024. PMID: 39330894 Free PMC article. Review.
-
Glycolytic shift during West Nile virus infection provides new therapeutic opportunities.J Neuroinflammation. 2023 Sep 27;20(1):217. doi: 10.1186/s12974-023-02899-3. J Neuroinflammation. 2023. PMID: 37759218 Free PMC article.
-
Transcriptome analysis reveals organ-specific effects of 2-deoxyglucose treatment in healthy mice.PLoS One. 2024 Mar 7;19(3):e0299595. doi: 10.1371/journal.pone.0299595. eCollection 2024. PLoS One. 2024. PMID: 38451972 Free PMC article.
References
-
- COVID Pandemic Data. [(accessed on 14 July 2022)]. Available online: https://en.wikipedia.org/wiki/Template:COVID-19_pandemic_data.
-
- Lauer S.A., Grantz K.H., Bi Q., Bi Q., Jones F.K., Zheng Q., Meredith H.R., Azman A.S., Reich N.G., Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicity reported confirmed cases: Estimation and application. Ann. Intern. Med. 2020;172:577–582. doi: 10.7326/M20-0504. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous